YuanDa Pharmaceutical: Introducing the world's first adrenaline nasal spray to treat severe allergic reactions.

On December 23rd, Yuandai Pharmaceuticals announced that it has reached a product collaboration agreement with Yuer Pharmaceuticals. Yuandai Pharmaceuticals will obtain the exclusive commercialization rights for Neffy adrenaline nasal spray, the world's first for emergency treatment of Type I allergic reactions, within its cooperation channels in mainland China, as well as non-exclusive commercialization rights in Hong Kong. This collaboration covers two specifications, 2mg and 1mg, suitable for adults and children weighing over 30kg, and children weighing 15-30kg. Ominsor has already submitted a market application to the National Medical Products Administration in December 2024 and has been accepted.